

Oxytocin Formulation

Version Revision Date: SDS Number: Date of last issue: 12/04/2024
3.0 04/14/2025 3447207-00015 Date of first issue: 09/26/2018

SECTION 1. IDENTIFICATION

Product name : Oxytocin Formulation
Other means of identification : No data available

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 37 McCarville Street
 : Charlottetown, PE C1E 2A7
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations

Not a hazardous substance or mixture.

GHS label elements

No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	Common Name/Synonym	CAS-No.	Concentration (% w/w)
Oxytocin, monoacetate (salt)	No data available	6233-83-6	$\geq 0 - < 0.1$ *

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
 : Get medical attention if symptoms occur.
In case of skin contact : Wash with water and soap as a precaution.
 : Get medical attention if symptoms occur.
In case of eye contact : Flush eyes with water as a precaution.
 : Get medical attention if irritation develops and persists.
If swallowed : If swallowed, DO NOT induce vomiting.
 : Get medical attention if symptoms occur.
 : Rinse mouth thoroughly with water.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

Most important symptoms and effects, both acute and delayed : None known.

Protection of first-aiders : No special precautions are necessary for first aid responders.

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : No hazardous combustion products are known

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g., by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.

Oxytocin Formulation

Version 3.0 Revision Date: 04/14/2025 SDS Number: 3447207-00015 Date of last issue: 12/04/2024
Date of first issue: 09/26/2018

Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : Use only with adequate ventilation.
Advice on safe handling : Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage : Keep in properly labeled containers.
Store in accordance with the particular national regulations.
Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Oxytocin, monoacetate (salt)	6233-83-6	STEL	50 ng/m ³ (OEB 5)	Internal
		Wipe limit	500 ng/100 cm ²	Internal

Engineering measures : The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.
Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace.
All engineering controls should be implemented by facility

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

design and operated in accordance with GMP principles to protect products, workers, and the environment.
No open handling permitted.
Totally enclosed processes and materials transport systems are required.
Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection	:	No personal respiratory protective equipment normally required.
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac-	:	Can react with strong oxidizing agents.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

tions
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Oxytocin, monoacetate (salt):

Acute oral toxicity	: LD50 (Mouse): > 514 mg/kg LD50 (Rat): > 21 mg/kg
Acute toxicity (other routes of administration)	: LD50 (Mouse): > 514 mg/kg Application Route: Subcutaneous LD50 (Mouse): 5.8 mg/kg Application Route: Intravenous LD50 (Rat): > 21 mg/kg Application Route: Subcutaneous LD50 (Rat): 2.3 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

Components:

Oxytocin, monoacetate (salt):

Genotoxicity in vitro	:	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: negative
-----------------------	---	---

Carcinogenicity

Not classified based on available information.

Reproductive toxicity

Not classified based on available information.

Components:

Oxytocin, monoacetate (salt):

Effects on fetal development	:	Test Type: Development Species: Rat Application Route: Subcutaneous Developmental Toxicity: NOAEL: 1 mg/kg body weight Result: No effects on fetal development.
------------------------------	---	---

Reproductive toxicity - Assessment	:	May damage the unborn child.
------------------------------------	---	------------------------------

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Oxytocin, monoacetate (salt):

Species	:	Rat
LOAEL	:	5 µg/kg
Application Route	:	Subcutaneous
Exposure time	:	5 Days
Target Organs	:	Endocrine system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Oxytocin, monoacetate (salt):

Inhalation	:	Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing
------------	---	---

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

Ingestion	: Target Organs: Gastrointestinal tract Symptoms: Nausea, Vomiting Target Organs: Central nervous system Symptoms: behavioral abnormalities Target Organs: Cardio-vascular system Symptoms: Increased heart rate, May cause cardiac arrhythmia., hypotension, tachycardia, flushing Target Organs: Gastrointestinal tract Symptoms: Nausea, Vomiting
-----------	---

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Oxytocin, monoacetate (salt):

Ecotoxicology Assessment

Acute aquatic toxicity	: Toxic effects cannot be excluded
Chronic aquatic toxicity	: Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Oxytocin, monoacetate (salt):

Partition coefficient: n-octanol/water	: log Pow: 6.27
--	-----------------

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	: Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

TDG

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New

SAFETY DATA SHEET

according to the Hazardous Products Regulations



Oxytocin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 12/04/2024
3.0	04/14/2025	3447207-00015	Date of first issue: 09/26/2018

Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 04/14/2025
Date format : mm/dd/yyyy

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8